NCT03503630进行中（未招募）2 期
Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma
Ali Shamseddine3 个研究点 分布在 2 个国家目标入组 44 人开始时间: 2018年7月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 44
- 试验地点
- 3
- 主要终点
- The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then mFOLFOX-6/COMPOUND 2055269
研究概览
简要总结
The purpose of this study is to show that the addition of COMPOUND 2055269, an immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response rate in patients with locally advanced rectal cancer.
详细描述
The purpose of this study is to show that the addition of COMPOUND 2055269, an immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response rate in patients with locally advanced rectal cancer.
COMPOUND 2055269 has demonstrated meaningful clinical activity across various tumor types and treatment settings. No clinical trial is conducted over COMPOUND 2055269 in locally-advanced rectal adenocarcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged ≥18 years.
- •Locally-advanced rectal cancer (cT2 N1-3, cT3 N0-3, evidence of extramural vascular or mesorectal fascia involvement).
- •<12 cm from anal verge.
- •Histologically proven rectal adenocarcinoma.
- •ECOG performance score ≤
- •Have adequate organ function by meeting the following:
- •Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;
- •Platelet count ≥ 100 × 109/L;
- •Hemoglobin ≥ 9 g/dL;
- •Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range;
- •AST and ALT levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver);
- •Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft- Gault formula (or local institutional standard method).
- •Negative serum or urine pregnancy test at screening for women of childbearing potential.
- •Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last COMPOUND 2055269 treatment administration if the risk of conception exists.
排除标准
- •Distant metastasis (M1).
- •Patients with T2 N0 or T
- •Recurrent rectal cancer.
- •Symptoms or history of peripheral neuropathy.
- •Prior radiotherapy or chemotherapy.
- •Current use of immunosuppressive medication, except for the following:
- •Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intraarticular injection);
- •Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent;
- •Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- •Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
- •Vaccination within 4 weeks of the first dose of COMPOUND 2055269 and while on trials is prohibited except for administration of inactivated vaccines.
- •Active infection requiring systemic therapy.
- •Known history of testing positive for the human immunodeficiency virus or known acquired immunodeficiency syndrome.
- •Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
- •Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3).
- •Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
- •Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
- •Prior organ transplantation including allogenic stem-cell transplantation.
- •Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •Concurrent treatment with a non-permitted drug.
- •Patients suspected by the physician that he/she will not compliant to the protocol conduct.
- •Pregnant or breastfeeding patients.
- •Patient participating in another clinical trial.
- •Patient who is not willing to sign the consent form.
- •Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- •Legal incapacity or limited legal capacity patients receiving other oncology specific medication not authorized in the protocol.
研究组 & 干预措施
Locally advanced rectal cancer patients
Experimental
- Week 1: D1-5: radiotherapy 25 Gy in 5 fractions
- mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)
- Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision
干预措施: COMPOUND 2055269 (Drug)
Locally advanced rectal cancer patients
Experimental
- Week 1: D1-5: radiotherapy 25 Gy in 5 fractions
- mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)
- Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision
干预措施: Radiation Therapy (Radiation)
Locally advanced rectal cancer patients
Experimental
- Week 1: D1-5: radiotherapy 25 Gy in 5 fractions
- mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)
- Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision
干预措施: mFOLFOX (Drug)
Locally advanced rectal cancer patients
Experimental
- Week 1: D1-5: radiotherapy 25 Gy in 5 fractions
- mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)
- Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision
干预措施: Total Mesorectal Excision (Procedure)
结局指标
主要结局
The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then mFOLFOX-6/COMPOUND 2055269
时间窗: After 17 weeks (once surgery is done)
Will be done via pathologic assessment on the surgical specimen
次要结局
- The proportion of patients who remain progression free at 3 years.(3 years)
- PD-L1 expression and T-cell infiltration changes after treatment(At day 10 biopsy and after 17 weeks (once surgery is done))
- Number of participants with treatment- related adverse events as assessed by NCI-CTCAE v4.0(3 years)
- Quality of life of the patients in a neoadjuvant setting with COMPOUND 2055269 as assessed by FACT-C questionnaire(3 years)
研究者
Ali Shamseddine
Principal Investigator
American University of Beirut Medical Center
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS TumoursMetastatic Colorectal CancerNCT01161316Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)194
进行中（未招募）
2 期
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal AdenocarcinomaAdenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Gastric CardiaStage IIIA Esophageal CancerStage IIIB Esophageal CancerStage IIIC Esophageal CancerNCT02037048Case Comprehensive Cancer Center63
已完成
2 期
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal CancerColon CancerNCT00193219SCRI Development Innovations, LLC36
撤回
2 期
Colorectal Cancer RECHALLENGEColorectal NeoplasmsNCT00988897Sanofi
撤回
2 期
FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal CarcinomaColorectal CarcinomaLiver MetastasesNCT00735241Sirtex Medical